Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2020
Emerging Company Profile
Quenching the flames of inflammatory cell death
With a $50M round, Quench is developing first-in-class gasdermin D inhibitors to treat inflammatory diseases.
BioCentury | Jan 7, 2020
Finance
BioIntervene takes on adenosine in pain, raises $30M
BioIntervene founder pinpoints an adenosine receptor that may be able to safely treat neuropathic pain
BioCentury | Dec 9, 2019
Company News
Novartis downsizing internal efforts on CAR T in solid tumors
How Novartis is shifting gears with its CAR T development plans
Items per page:
1 - 10 of 48